About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 765 record(s)
Req # A-2019-001669
Adverse Reaction Report (AER). Report number: E2B_02564654.Organization: Health Canada
November 2020
Req # A-2019-001736
Adverse Reaction Reports (AERs) for ONDANSETRON. Report numbers: E2B_02774286, E2B_02774323, 2B_02791878.Organization: Health Canada
November 2020
Req # A-2019-001896
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02476924, E2B_02481998, E2B_02461156, E2B_02479081, E2B_02463587, E2B_02482940, E2B_02466363, E2B_02483006, E2B_02484843, E2B_02483189, E2B_02485557, E2B_02482851, E2B_02429206, E2B_02430330, E2B_02485567, E2B_02487053, 000723420, 000724387, E2B_02421973, E2B_02424538.Organization: Health Canada
November 2020
Req # A-2019-001898
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02262224, E2B_02319615, E2B_02318360, E2B_02323655, E2B_00804510, E2B_02401495, E2B_02404996, E2B_02405916, E2B_02405069, E2B_02405883, E2B_02399916, E2B_02404153, E2B_02406558, E2B_02401703, E2B_02401745, E2B_02405091, E2B_02405057, E2B_02405260, E2B_02404053, E2B_02405078.Organization: Health Canada
November 2020
Req # A-2019-001923
Adverse Reaction Reports (AERs) for Mezavant. Report numbers: 000730725, 000730743, E2B_02786248, E2B_02786540, E2B_02786618, E2B_02792266, E2B_02799140, E2B_02799243, E2B_02801137, E2B_02801978.Organization: Health Canada
November 2020
Req # A-2019-001953
Adverse Reaction Reports (AERs). Report numbers: 000727109, 000727133, E2B_02591901, 000728535, E2B_02673530, 000729225, 000704418, E2B_02759972, E2B_02120058, 000707184, E2B_01600174, 000708459, 000714865, E2B_01951071.Organization: Health Canada
November 2020
Req # A-2019-001970
Adverse Reaction Report (AER). Report number: 000730941.Organization: Health Canada
November 2020
Req # A-2019-001972
Adverse Reaction Report (AER). Report number: E2B_02782262.Organization: Health Canada
November 2020
Req # A-2019-002061
Adverse Reaction Reports (AERs) for ENTYVIO. Report numbers: E2B_02910855, E2B_02916121, E2B_02918668, E2B_02903656, E2B_02913143.Organization: Health Canada
November 2020
Req # A-2019-002062
Adverse Reaction Reports (AERs) for VEDOLIZUMAB. Report numbers: E2B_02886208, E2B_02906274, E2B_02869094, E2B_02887283, E2B_02891420, E2B_02867066, E2B_02891996, E2B_02881020, E2B_02907681, E2B_02880510, E2B_02885532, E2B_02878124, E2B_02872742.Organization: Health Canada
November 2020